Unum Group

Unum Group announced a new US$1.00 billion share repurchase authorization, while AM Best reaffirmed its A (Excellent) financial strength rating and stable outlook for the insurer's core U.S. subsidiaries. The new authorization adds to an already active buyback program that retired roughly US$600.7 million of stock in the first half of 2026, and it sits alongside a rising dividend. Unum Group's narrative projects $13.3 billion in revenue and $1.5 billion in earnings by 2029, requiring flat yearly revenue growth and an earnings increase of about $0.7 billion from $781.4 million today. Members of the Simply Wall St Community currently see Unum's fair value between about US$102 and US$158 across 2 independent views, with one forecast implying a $102.23 fair value, a 7% upside to its current price. The main watchpoint remains potential pressure on benefit ratios and net margins if claims trends worsen, though the rating reaffirmation does not materially change that risk.

Unum Group has announced a new $1 billion share repurchase authorization, approved by its board on August 26, 2026, to take effect September 1, 2026, immediately after the current program expires on August 31. The company repurchased 7.9 million shares for approximately $604.5 million in the first half of 2026, leaving about $401.5 million under the existing authorization as of June 30. Unum's weighted-average risk-based capital ratio for its traditional U.S. insurance subsidiaries stood at approximately 480% as of June 30, providing a strong capital cushion. The new buyback is part of a broader capital-allocation strategy that balances repurchases, dividends, and business investments. Unum's shares have gained 32% in the past year, and the stock trades at a forward price-to-book value of 1.34X, below the industry average of 1.69X. However, the Zacks Consensus Estimate for Unum's third-quarter and fourth-quarter 2026 EPS has moved down 2.2% and 2.7% respectively in the past 30 days, and the stock currently carries a Zacks Rank #4 (Sell).

Unum Group has agreed to reinsure an additional $3.8 billion of long-term care statutory reserves with Fortitude Re, bringing total reinsured long-term care reserves to $7 billion and reducing its exposure by 40% from the start of last year. The transaction, effective April 1, 2026, and expected to close during 2026, removes all of Unum's remaining individual long-term care business from Fairwind, leaving mainly group long-term care there. Following the deal, total long-term care statutory reserves are expected to fall from $14.8 billion to approximately $11 billion, with group long-term care representing about 70% of remaining reserves. Unum said the transaction will use $650 million of holding company excess capital, but capital return plans remain unchanged, including about $1.3 billion in expected dividends and share buybacks in 2026.

Unum Group's fair value estimate has been increased to approximately $100.08, aligning with a refreshed $100 price target, following a $3.8 billion long term care reserve cession to Fortitude Re. The deal prompted several analysts to raise their price targets, with Jefferies lifting its target to $123 from $117, Barclays to $110 from $105, and Evercore ISI to $106 from $103, while Wolfe Research adjusted its target to $100 from $102 and maintained an Outperform rating, arguing the transaction reinforces the view that Unum's long term care block is transactable and could make the company a stronger takeout candidate. The fair value revision also reflects a slightly improved long term revenue growth outlook, now projecting an annual decline of about 11.0% versus 11.08% previously, and a modest uptick in forecast net profit margin to around 11.16% from 11.11%, with the future P/E multiple moving to about 10.85x from 10.64x. Some caution persists, as Wolfe Research noted Unum shares underperformed on the announcement date, suggesting some investors may be assigning less value to future reserve deal catalysts.

Unum Group declared a quarterly dividend of $0.505 per share and announced a $3.8 billion long term care reinsurance deal. The stock has returned 14.13% over the past 90 days and 278.22% over five years. At a current share price of $87.50, a discounted cash flow model from Simply Wall St estimates a fair value of $169.65 per share, implying a 48.4% discount. However, the stock trades at a price-to-earnings ratio of 17.9 times, above the US insurance industry average of 12.3 times and a peer average of 17.4 times, and above an estimated fair P/E of 14.6 times.

Unum Group has promoted Andrew Walker to Executive Vice President, Chief Customer Operations Officer. Walker joined the company in 2025 as Senior Vice President in the same role and has since focused on strengthening operational performance and simplifying processes. In his expanded capacity, he will continue to lead Customer Operations, including benefit operations, service delivery and transformation initiatives. Prior to Unum, Walker served as Executive Vice President and Chief Operations Officer at Western Union and held senior operations roles at USAA and Nationwide.

A bullish thesis on Unum Group highlights the insurer's defensive workplace benefits franchise and dividend compounding potential. The company operates in the U.S. and U.K., specializing in disability, life, dental, and voluntary employee benefits distributed through employer payroll systems, creating a sticky customer base with low churn. Unum offers a 2.26% dividend yield, $1.84 annual dividend per share, 17 consecutive years of dividend increases, and a five-year dividend growth rate of 54%. In Q1 2026, it reported revenue of $3.36 billion, net income of $232 million, and after-tax adjusted operating income of $352.5 million, with net premiums earned of $2.79 billion. The company reaffirmed 2026 guidance for 4% to 7% revenue growth and 8% to 12% EPS growth, supported by 22% growth in U.S. Group sales and 92% persistency.

Unum Group shares have gained 16.8% over the past year, outpacing the industry's 15.4% growth and closing Wednesday at $91.62, just shy of a 52-week high of $93.22. The stock is supported by strong premium growth, favorable disability claims, robust sales momentum, and aggressive capital returns, with earnings growing 10.6% over five years versus the industry's 0.6%. Based on 13 analysts, the Zacks average price target is $96.77, implying a 5.6% upside, while the stock trades at a price-to-book of 1.34, below the industry's 1.73. The Zacks Consensus Estimate for 2026 revenues is $11.9 billion, a 10.3% decline, but EPS is expected to rise 7.8%, with a long-term earnings growth rate of 11.3% exceeding the industry's 9.7%. Despite mixed analyst revisions and risks from competitive pricing and rising expenses, the company's premium growth outlook of 4-7% for 2026 and adjusted operating income per share guidance of $8.60 to $8.90 support a Zacks Rank #3, or Hold, rating.